

**NMI Antibody (N-term)**  
**Affinity Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP19351a**

**Specification**

---

**NMI Antibody (N-term) - Product Information**

|                   |                             |
|-------------------|-----------------------------|
| Application       | WB,E                        |
| Primary Accession | <a href="#">Q13287</a>      |
| Other Accession   | <a href="#">NP_004679.2</a> |
| Reactivity        | Human                       |
| Host              | Rabbit                      |
| Clonality         | Polyclonal                  |
| Isotype           | Rabbit IgG                  |
| Calculated MW     | 35057                       |
| Antigen Region    | 1-30                        |

**NMI Antibody (N-term) - Additional Information**

**Gene ID** 9111

**Other Names**

N-myc-interactor, Nmi, N-myc and STAT interactor, NMI

**Target/Specificity**

This NMI antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human NMI.

**Dilution**

WB~~1:1000

E~~Use at an assay dependent concentration.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

NMI Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**NMI Antibody (N-term) - Protein Information**

**Name** NMI ([HGNC:7854](#))

**Function** Acts as a signaling pathway regulator involved in innate immune system response

(PubMed:[26342464](#), PubMed:[29038465](#), PubMed:[29350881](#), PubMed:[9989503](#)). In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis (PubMed:[29377960](#), PubMed:[9989503](#)). Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription (PubMed:[9989503](#)). In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 (PubMed:[10779520](#), PubMed:[10950963](#)). In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21 (PubMed:[26342464](#)). In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed:[29350881](#)). Negatively regulates virus-triggered type I interferon/IFN production by inducing proteasome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses (By similarity). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion (PubMed:[29038465](#)). Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro- inflammatory cytokines (PubMed:[29038465](#)).

#### **Cellular Location**

Cytoplasm. Nucleus. Secreted Note=Cytoplasmic NMI localizes in punctate granular structures (PubMed:[10950963](#), PubMed:[9781816](#)). Nuclear localization increased following IFN-alpha treatment (PubMed:[10950963](#), PubMed:[9781816](#)) Extracellular following secretion by macrophage (PubMed:[29038465](#))

#### **Tissue Location**

Expressed in adult spleen, liver, and kidney (PubMed:[9781816](#)). Expressed in fetal thymus, liver, placenta, spleen, lung, and kidney but not brain (PubMed:[9781816](#)). Expressed in macrophages (PubMed:[29038465](#)).


#### **NMI Antibody (N-term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### **NMI Antibody (N-term) - Images**





NMI Antibody (N-term)(Cat. #AP19351a) western blot analysis in WiDr cell line lysates (35ug/lane). This demonstrates the NMI antibody detected the NMI protein (arrow).

#### **NMI Antibody (N-term) - Background**

NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. The NMI protein also interacts with all STATs except STAT2 and augments STAT-mediated transcription in response to cytokines IL2 and IFN-gamma. The NMI mRNA has low expression levels in all human fetal and adult tissues tested except brain and has high expression in cancer cell line-myeloid leukemias. [provided by RefSeq].

#### **NMI Antibody (N-term) - References**

Davila, S., et al. Genes Immun. 11(3):232-238(2010)  
Fillmore, R.A., et al. Int. J. Cancer 125(3):556-564(2009)  
Quaye, L., et al. Br. J. Cancer 100(6):993-1001(2009)  
Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009)  
Quaye, L., et al. Clin. Cancer Res. 14(18):5833-5839(2008)